Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Total Non-Current Liabilities (2016 - 2025)

Fate Therapeutics' Total Non-Current Liabilities history spans 14 years, with the latest figure at $111.5 million for Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities fell 4.64% year-over-year to $111.5 million; the TTM value through Dec 2025 reached $111.5 million, down 4.64%, while the annual FY2025 figure was $111.5 million, 4.64% down from the prior year.
  • Total Non-Current Liabilities reached $111.5 million in Q4 2025 per FATE's latest filing, up from $103.0 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $262.8 million in Q2 2021 to a low of $103.0 million in Q3 2025.
  • Average Total Non-Current Liabilities over 5 years is $169.5 million, with a median of $143.1 million recorded in 2023.
  • Peak YoY movement for Total Non-Current Liabilities: skyrocketed 150.36% in 2021, then plummeted 39.14% in 2023.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $218.4 million in 2021, then decreased by 0.31% to $217.8 million in 2022, then plummeted by 37.34% to $136.5 million in 2023, then fell by 14.33% to $116.9 million in 2024, then fell by 4.64% to $111.5 million in 2025.
  • Per Business Quant, the three most recent readings for FATE's Total Non-Current Liabilities are $111.5 million (Q4 2025), $103.0 million (Q3 2025), and $104.7 million (Q2 2025).